A multicentre, double-blind, randomized, placebo-controlled, parallel group trial to investigate the efficacy and safety of lacosamide (200, 400 or 600 mg/day) as adjunctive therapy in subjects with partial seizures.
Phase of Trial: Phase III
Latest Information Update: 01 Nov 2015
At a glance
- Drugs Lacosamide (Primary)
- Indications Partial epilepsies
- Focus Registrational; Therapeutic Use
- 05 Nov 2010 New trial record.